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Mast cell disorders are deﬁned by an abnormal accumulation of tissue mast cells in one or more organ systems. In systemic
mastocytosis, at least one extracutaneous organ is involved by deﬁnition. Although, systemic mastocytosis usually represents with
skinlesioncalled urticaria pigmentosa,in a smallproportion, there is extracutaneous involvementwithout skininﬁltration.Other
manifestations are ﬂushing, tachycardia, dyspepsia, diarrhea, hypotension, syncope, and rarely fever. Various medications have
been used but there is not a deﬁnite cure for systemic mastocytosis. The principles of treatment include control of symptoms
with measures aimed to decrease mast cell activation. We describe a case of systemic mastocytosis presenting with hypotension,
syncope attacks, fever, and local ﬂushing. In bone marrow biopsy, increased mast cell inﬁltration was demonstrated. She had
no skin inﬁltration. A good clinicopathological response was obtained acutely with combination therapy of glucocorticoid and
cyclosporine.
1.Introduction
Mastocytosis is a rare hematopoietic disorder which is
characterized by abnormal proliferation and accumulation
of mast cells in one or more organs [1]. Mast cell disorders
are recently included under the category of myeloprolifer-
ative neoplasms by the 2008 World Health Organization
classiﬁcation of myeloid neoplasms [2]. Mastocytosis limited
to the skin is called cutaneous mastocytosis, and when
extracutaneous organs such as bone marrow, liver, spleen,
or gastrointestinal tract are involved, it is called systemic
mastocytosis (SM) [3]. Cutaneous mastocytosis is largely a
disease of infancy and childhood, while SM is usually seen
in adults. Systemic mastocytosis which accounts for about
10% of all cases of mastocytosis is a persistent disease that
can follow benign or indolent course or may be associated
with hematological disorders. Major clinical manifestations
of SM are episodic ﬂushing, dyspepsia, diarrhea, abdominal
pain, tachycardia, and pruritus [4]. These are related directly
to tissue inﬁltration or to the release of mast cell mediators
like leukotrienes and histamine.
Here, we report an SM patient presenting with ﬂushing,
hypotension, fever, and syncope attacks. Her symptoms
have been successfully controlled and mast cell inﬁltration
in bone marrow decreased signiﬁcantly after short-term
corticosteroid and cyclosporine treatment.
2.Case Report
A 52-year-old woman presented with fatigue, ﬂushing,
dyspepsia, hypotension, and syncope attacks for about 182 Case Reports in Medicine
Figure 1: Flushing in face, neck, and upper chest with sharp mar-
gins.
months. She deﬁned headache and fatigue at the beginning
of attack, and then ﬂushing occurred in her face and neck
primarily, descending to body but not to extremities. During
attacks, she had hypotension with systolic blood pressure
between 50–70mmHg, diastolic blood pressure between
20–40mmHg, and followed by 5–10 minutes of syncope.
While ﬂushing resolved in about an hour, she sometimes
had diarrhea, dyspepsia, nausea, and vomiting before or just
after the attacks. After she had experienced fever reaching
39◦C in the last attack, she was referred to our hospital.
In the 11th day of hospitalization, she developed nausea,
vomiting,andfeverof40◦Congoingwithseverehypotension
(systolic and diastolic blood pressures of 50mmHg and
25mmHg, resp.). She had conjunctival hyperemia and ﬂush-
ing in her face, neck, and upper chest with sharp margins
(Figure 1). She was transferred to critical care unit for
close monitorization and management of hemodynamic
instability. With intravenous ﬂuid replacement therapy, her
blood pressure increased up to 120/70mmHg and hemo-
d y n a m i cs t a b i l i t yw a sa c h i e v e di na nh o u r .T h e r ew a sn o
pneumonic inﬁltration and blood and urine cultures were
negative for any microorganism. Thoracoabdominal com-
puted tomography was normal. Transesophageal echocar-
diography revealed no vegetation. Carcinoid syndrome and
pheochromocytoma were excluded based on normal urine
catecholamines and 5-hydroxyindoleacetic acid checked
before and during the ﬁrst 4 hours of the attack. Bone
marrow aspiration and biopsy were performed because
of anemia (hemoglobin=6.9mg/dl) and thrombocytopenia
(110.000/μL)(Table 1). Bone marrow aspiration showed that
80% of nucleated cells were mast cells (Figure 2), and biopsy
revealed a hypercellular bone marrow inﬁltrated with mast
cells. In addition, c-kit staining was positive in bone mar-
row biopsy, immunohistochemically. Serum tryptase and
histamine levels at the time of attack were >200ng/mL
Figure 2: Inﬁltration with mast cells in bone marrow aspiration
(original magniﬁcation ×1000).
(<13.5ng/mL) and >100nmol/L (<10nmol/L), respectively.
Her serum hemoglobin and platelet concentrations returned
to acceptable levels without any transfusion in a few days
(hemoglobin=8.9g/dl and platelets=176.000/μL).
She was administered on prednisolone (1mg/kg/day)
and cyclosporine (300mg/d) with a H1 receptor blocking
agent (desloratadine 5mg/day). After esophagogastroduo-
denoscopy, an H2 receptor blocking agent (famotidine
80mg/day) was also initiated since she had duodenal ulcer.
After three weeks of corticosteroid and cyclosporine treat-
ment, repeated bone marrow biopsy showed normal mor-
phology and in aspiration mast cells constituted 15% of
nucleated cells. Serum tryptase level was still >200ng/mL;
however, histamine level decreased to 29.7nmol/L. About 10
weeks after she was discharged from the hospital, Fip1-like1
(FIP1L1) gene mutation analysis was found to be negative
and she was administered on interferon alpha treatment. She
wasfreeofanyattacksorothersymptomsforabout5months
and in the last visit her serum hemoglobin and platelet levels
were 10.9g/dl and 238.000/μL, respectively.
3.Discussion
Diagnosis of SM is conﬁrmed with evidence of involvement
of a tissue other than skin, most commonly bone marrow,
spleen, liver, lymph node, and gastrointestinal tract. Main
symptomsrelatedtomastcelldegradationareepisodicﬂush-
ing caused by vasodilatation, dyspepsia, nausea, vomiting,
diarrhea, and abdominal pain. There may be associated
hypotension and syncope due to cerebral hypoperfusion.
Suchanacuteattacktypicallylasts from 15to30minutesand
m a yb ep r e c i p i t a t e db yav a r i e t yo ft r i g g e r ss u c ha sp h y s i c a l
exertion, emotional upset, heat, cold, ethanol, intravenous
contrast exposure, and certain medications (nonsteroidal
anti-inﬂammatory drugs, opioids, and general anesthetics).
In our patient, attacks of ﬂushing, hypotension, and syncope
with nonspeciﬁc symptoms like fatigue, diarrhea, nausea,
vomiting,anddyspepsiawereallsuggestiveforSM.Although
fever is not a known classical symptom for SM, there areCase Reports in Medicine 3
Table 1: Laboratory data at ﬁrst admission, during attack and after treatment.
At the time of hospitalization During attack 3 weeks after treatment
Complete blood count:
Hemoglobin (12–18gr/dl) 9.5 6.9 11.9
Hematocrit (36–54%) 27.5 18.8 33.5
Erythrocyte (3.5–6.0×106/mcl) 2.97 2.02 3.24
White blood cells (3600–10000/mcl) 13600 9100 11200
Neutrophile (37–75%) 86.3 72.0 73.7
Lymphocyte (20–55%) 8.1 9.0 22.0
Monocyte (2.5–10%) 1.0 4.7 2.2
Eosinophil (0.5–11%) 4.6 5.7 2.1
Basophil (0–2%) 0.0 8.6 0.0
Platelet (150.000–450.000/mcl) 286.000 110.000 234.000
Erythrocyte sedimentation rate (0–20 mm) 33 7 21
Tryptase (<13.5ng/mL) — >200 >200
Histamine (<10nmol/L) — >100 29.7
limited numbers of cases that presented with fever in the
literature [5, 6]. Our patient also had a body temperature
reaching 39◦C in her last two severe attacks.
Skin lesions may or may not accompany SM. Although
urticaria pigmentosa which is known to be the character-
istic lesion of mastocytosis was described in 80% of SM
patients previously [7], recently Lim et al. showed that 41%
of patients with SM had urticaria pigmentosa and 53% had
cutaneous symptoms including pruritus, ﬂushing, urticaria,
or angioedema [8]. It is considered that more aggressive
forms of SM which have unfavorable prognosis are more
likely to present without cutaneous lesions [9]. There was no
skin lesion except intermittent and temporary ﬂushing and
urticarial rash in our patient, and Darier’ sign was negative.
Diﬀuse erythema during attacks were supposed to result
from histamine release rather than skin inﬁltration by mast
cells.
The major criterion for diagnosis of SM is the ﬁnding
of multifocal dense inﬁltrates of mast cells in bone marrow
or other extracutaneous tissues. There are also 4 minor
criteria deﬁned as follows: (a) atypical mast cell morphology,
(b) aberrant mast cell surface immunophenotype, (c) serum
total tryptase >20ng/mL, and (d) c-kit mutation at codon
816 in extracutaneous organs [10]. If at least one major
and one minor criterion or at least three minor criteria are
fulﬁlled,theﬁnaldiagnosisofSMcanbeconﬁrmed.Tryptase
which is stored almost exclusively within the secretory
granules of mast cells is the most widely used marker
of mastocytosis. In healthy individuals, serum tryptase
levels range between <1 and 15ng/mL; however, mast cell
activation causes increased tryptase levels [11]. Additionally,
tryptase levels in SM are assumed to correlate closely with
thecumulativemastcellburdenandmultiorganinvolvement
[5]. Mast cell inﬁltration of bone marrow has been shown in
our patient. Additionally, high serum tryptase (>200ng/mL)
levels and positive c-kit staining in bone marrow biopsy
conﬁrmed our diagnosis. However, we could not make
analysis for D816V c-kit mutation due to technical reasons.
World Health Organization classify 7 types of masto-
cytosis: cutaneous mastocytosis, indolent SM, SM with an
associated clonal hematological nonmast cell lineage disease,
aggressive SM, mast cell leukemia, mast cell sarcoma, and
extracutaneous mastocytoma [12]. Cutaneous mastocytosis
is an indolent disease which can only be diagnosed when SM
is excludedby appropriateinvestigations. The most common
variant of SM is indolent SM which is diﬀerentiated from
more advanced categories of SM by lack of end organ dys-
functions and relatively low inﬁltration grade.Aggressive SM
is characterized byevidenceofendorgan dysfunction suchas
signiﬁcant cytopenia, ascites, malabsorption, splenomegaly,
or pathologic fractures due to osteolysis. If mast cells
comprise>20%ofallnucleatedcellsinbonemarrowaspirate
a n da r ei n c r e a s e di nc i r c u l a t i o nw i t h≥10% mast cells in
peripheral blood, this is called mast cell leukemia. SM in our
patient was subtyped as mast cell leukemia as 80% of bone
marrow aspirate was composed of mast cells.
Modalities used in the treatment of SM are directed to
two targets: symptomatic control and decrease in mast cell
burden. Commonly used medications for symptomatic relief
are H1 and H2 antihistamines, oral disodium cromogly-
cate, and epinephrine for hypotensive episodes. However,
currently there is no cure for more serious types of SM.
Interferon alpha is the drug for which most experience has
been reported, but there are conﬂicting results about it [13–
15]. Combination of interferon alpha with corticosteroid has
also been shown to have a beneﬁcial eﬀect in controlling
symptoms of SM [16]. Cladribine and imatinib mesylate
are other two cytoreductive agents recently used for SM
patients and showed promising results [17, 18]. It was found
that patients with a gene translocation resulting in fusion of
the FIP1L1 gene and platelet-derived growth factor (PDGF)
receptor alpha genes respond well to imatinib mesylate
[19]. However, the major problem with that drug is that
patients that are positive for D816V c-kit mutation are
usually resistant to its eﬀects[20]. In the literature, we found
one patient with aggressive SM showing a good response4 Case Reports in Medicine
to cyclosporine and corticosteroid treatment [21]. We also
treated our patient with corticosteroid and cyclosporine in
the early period. Bone marrow biopsy after three weeks
of this therapy showed signiﬁcant reduction in mast cell
burden. Besides, the patient was nearly asymptomatic after
a few days of therapy. In followup, based on negative
FIP1L1-PDGFR mutation analysis, she was administered on
interferon alpha treatment.
4.Conclusion
Systemic mastocytosis without skin involvement may rep-
resent with attacks of ﬂushing, hypotension, syncope, and
fever mimicking septic shock or cardiovascular collapse.
Combination therapy with corticosteroid and cyclosporin
seems to help to control symptoms and decrease mast cell
burden in a short time.
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